Sankyo Sues Nissin Over Mevalotin Patent

Law360, New York (April 20, 2004, 12:00 AM EDT) -- Japanese drug maker Sankyo has filed a lawsuit against domestic rival Nissin Pharmaceutical over its flagship hyperlipidaemia drug Mevalotin (pravastatin), which Sankyo developed after discovering the world’s first cholesterol inhibitor.

Sankyo’s action follows Nissin’s recent launch of a generic version of the product, called Mevarich, following the expiration of Mevalotin's patent in October 2002.

With the main patent expired, Sankyo is suing Nissin based on a patent for the technology to keep Mevalotin tablets stable.

Around 30 companies are currently developing generic versions of Mevalotin with...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.